HPV Genotype Attribution and Disease Burden of Anal Cancer in China
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Anal Cancer. Basic parameters: No limits · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Understanding the Human Papillomavirus Genotype Attribution and Disease Burden of Anal Cancer in China: A Multicenter Hospital-based Study
Overview
To demonstrate HPV prevalence and its genotype distributions in anal cancer in China and to describe demographic and clinical features of HPV-related anal cancer in China; To describe the epidemiological characteristics ,trends and of disease burden of anal cancer in China
Primary outcome measures
- Prevalence and types of distribution of HPV [Time frame: From enrollment to pre-treatment]
- Incidence of anal-cancers-associated complications [Time frame: From enrollment to pre-treatment]
- Routine laboratory testing results [Time frame: From enrollment to pre-treatment]
Secondary outcome measures (3)
- Incidence rates of anal cancer in China [Time frame: From enrollment to pre-treatment]
- Mortality rate of anal cancer in China [Time frame: From enrollment to pre-treatment]
- Annual percentage changes (APCs) and average APCs (AAPCs) [Time frame: From enrollment to pre-treatment]
Eligibility criteria
Inclusion criteria
- (1) Patients diagnosed with anal cancers, (2) Patients without radiation or chemotherapy prior to specimen collection;
Exclusion criteria
- (1) Patients with HIV infection, (2) Patients with immunosuppression after solid organ transplantation, (3) Those who do not agree to specimen collection and testing, (4) For retrospective study cases, those who without specimen.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Case-only
Study locations
China · 1 center
- Fudan University Shanghai Cancer Center — Shanghai
Identifiers
NCT: NCT06670495 · 2024-225-3778